Gelesis Holdings, Inc. (GLSHQ)

USD 0.0

(0.0%)

Market Cap (In USD)

733.00

Revenue (In USD)

25.76 Million

Net Income (In USD)

-57.12 Million

Avg. Volume

-

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-6-0.02
PE
-
EPS
-
Beta Value
3556.772
ISIN
US36850R2040
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Yishai Zohar
Employee Count
-
Website
https://www.gelesis.com
Ipo Date
2020-08-24
Details
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.